This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Zogenix And Battelle To Present Positive, New Data Demonstrating Value Of Needle-Free Injection For Biologics

SAN DIEGO and COLUMBUS, Ohio, May 20, 2013 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX) and Battelle Memorial Institute today announced new data supporting the value of the DosePro® needle-free injection technology in the delivery of biologics. The positive, new data will be presented in four poster presentations, including two posters co-authored by MedImmune, LLC, the worldwide biologics research and development arm of AstraZeneca plc, and Zogenix; and two posters co-authored by Battelle and Zogenix, at the 2013 American Association of Pharmaceutical Scientists (AAPS) National Biotechnology Conference, May 20-22, 2013 in San Diego.

The data presented in these posters show that the DosePro technology is compatible with monoclonal antibodies formulations and a range of biologic formulation viscosities which are challenging to deliver via standard autoinjector technologies. The studies found that injection of these formulations were within the acceptable criteria for injection time and peak pressure and that there were no changes in molecular integrity, observable tertiary structure, purity or potency following injection. The data also show that needle-free technology such as DosePro has the potential to positively impact patient acceptance of self-injectable therapies, leading to greater adoption and adherence of subcutaneously administered biologics.

John Turanin, Vice President and General Manager, DosePro Technology, at Zogenix, commented, "This new data represents an important step in addressing the need for delivery technology for biologics by demonstrating DosePro's compatibility with the viscous formulations and the impact of needle-free delivery on patient confidence. We believe the AAPS National Biotechnology Conference will be an excellent forum to introduce the DosePro system to potential biopharmaceutical partners looking for innovative delivery technology solutions for their current and future self-injection therapies."

The four posters to be presented at the AAPS National Biotechnology Conference include:
  • In Vitro Integrity of Two Recombinant Human Monoclonal Antibodies after Instantaneous Injection by DosePro® Delivery Technology; Poster# M1012  
  • Injection Performance Assessment of Monoclonal Antibody Formulation Viscosity mimics Using an Instantaneous Injection Technology; Poster# M1013  
  • Adoption, Adherence, and Preferences Regarding Injectable Drug Delivery by Patients with Rheumatoid Arthritis: Results of a Research Survey; Poster# T2010  
  • Devices for Delivery of Viscous Protein Formulations and their Impact on Protein Structure; Poster# T2012

Battelle will feature the DosePro system at its booth (#413) at the AAPS National Biotechnology Conference. For more information on licensing opportunities using the DosePro platform contact Battelle at 1-800-201-2011 or

About DosePro®

The DosePro system is a first-in-class, easy-to-use drug delivery system designed for self-administration of a pre-filled, single dose of sterile liquid drug, subcutaneously, without a needle. The platform is currently used by Zogenix's first commercial product, SUMAVEL DosePro ®. The Company believes that DosePro offers several benefits to patients compared to other subcutaneous needle-based delivery methods, and that it has the potential to become a preferred delivery option for patients and physicians. These benefits include less anxiety or fear due to the lack of a needle, easier disposal without the need for a sharps container, no risk of needle stick injury or contamination, an easy-to-use three step administration process, no need to fill the device prior to use, reliable performance, discreet use and portability. In several clinical trials and market research studies, DosePro has been shown to be preferred by patients over conventional needle-based systems.

About Zogenix

Zogenix, Inc. (Nasdaq:ZGNX), with offices in San Diego and Emeryville, California, is a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain. Zogenix's first commercial product, SUMAVEL® DosePro® (sumatriptan injection) Needle-free Delivery System, was launched in January 2010 for the acute treatment of migraine and cluster headache. Zogenix's lead investigational product candidate, Zohydro™ ER (hydrocodone bitartrate), is an oral, extended-release formulation of various strengths of hydrocodone, without acetaminophen, intended for administration every 12 hours for around the clock management of moderate to severe chronic pain. In May 2012, Zogenix submitted to the FDA a New Drug Application for Zohydro ER. Zogenix's second investigational product candidate, Relday™, is a proprietary, long-acting injectable formulation of risperidone for the treatment of schizophrenia; an investigational new drug application was submitted to the FDA in May 2012.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.70 -0.60%
FB $101.91 0.90%
GOOG $683.11 -0.15%
TSLA $150.47 4.73%
YHOO $26.76 -1.25%


Chart of I:DJI
DOW 15,660.18 -254.56 -1.60%
S&P 500 1,829.08 -22.78 -1.23%
NASDAQ 4,266.8370 -16.7550 -0.39%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs